Clinical trial
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With…
NCT00207155 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00207155 |
|---|---|
| Title | An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer |
| Official title | An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 110 |
| Start date | Dec 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Oct 28, 2015 |
| Countries | Canada, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: